{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:59Z","timestamp":1792782839676,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangxi Science and Technology Major Project","award":["GuikeAA23073013"],"award-info":[{"award-number":["GuikeAA23073013"]}]},{"name":"the Natural Science Foundation of Shandong Province","award":["ZR2023MH044"],"award-info":[{"award-number":["ZR2023MH044"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160589"],"award-info":[{"award-number":["82160589"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01698-9","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T04:35:30Z","timestamp":1747542930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Yubo","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuetao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"issue":"3","key":"1698_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1698_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"key":"1698_CR3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41575-021-00465-x","volume":"18","author":"C Wang","year":"2021","unstructured":"Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol. 2021;18:690\u2013704.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1698_CR4","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019. Epub 2018 Apr 5. Erratum in: J Hepatol. 2019;70(4):817.","DOI":"10.1016\/j.jhep.2018.03.019"},{"issue":"Suppl 1","key":"1698_CR5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.31327","volume":"73","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR. AASLD panel of experts on trial design in HCC. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology. 2021;73(Suppl 1):158\u201391.","journal-title":"Hepatology"},{"key":"1698_CR6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345\u201362.","journal-title":"Lancet"},{"key":"1698_CR7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, Pawlik TM. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410\u201320.","journal-title":"JAMA Surg"},{"issue":"4","key":"1698_CR8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M, Finn RS. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21(4):294\u2013311.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1698_CR9","volume":"11","author":"W Zhang","year":"2023","unstructured":"Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J Immunother Cancer. 2023;11(9): e007366.","journal-title":"J Immunother Cancer"},{"key":"1698_CR10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/hep.27548","volume":"61","author":"C Wang","year":"2015","unstructured":"Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ, Bai W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015;61:1579\u201390.","journal-title":"Hepatology"},{"key":"1698_CR11","first-page":"69","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"1698_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2023.0125","volume":"30","author":"K Sankar","year":"2024","unstructured":"Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, Hendifar AE, et al. Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2024;30:1\u201315.","journal-title":"Clin Mol Hepatol"},{"key":"1698_CR13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/17460441.2020.1696769","volume":"15","author":"Q Dai","year":"2020","unstructured":"Dai Q, Zhang C, Yuan Z, Sun Q, Jiang Y. Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opin Drug Discov. 2020;15:243\u201358.","journal-title":"Expert Opin Drug Discov"},{"key":"1698_CR14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1698_CR15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133\u201346.","journal-title":"Lancet"},{"key":"1698_CR16","volume":"11","author":"HC Sun","year":"2021","unstructured":"Sun HC, Zhu XD. Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: an overview. Front Oncol. 2021;11: 772195.","journal-title":"Front Oncol"},{"issue":"1","key":"1698_CR17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1499-3872(16)60174-1","volume":"16","author":"WY Lau","year":"2017","unstructured":"Lau WY, Lai EC, Lau SH. Associating liver partition and portal vein ligation for staged hepatectomy: the current role and development. Hepatobiliary Pancreat Dis Int. 2017;16(1):17\u201326.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"6","key":"1698_CR18","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.dld.2023.11.027","volume":"56","author":"X Li","year":"2024","unstructured":"Li X, Wang X, Bai T, Chen J, Lu S, Wei T, Tang Z, Zhao G, Lu H, Li L, Wu F. Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: a real-world observational study. Dig Liver Dis. 2024;56(6):1078\u201386.","journal-title":"Dig Liver Dis"},{"issue":"12","key":"1698_CR19","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1245\/s10434-007-9549-7","volume":"14","author":"WY Lau","year":"2007","unstructured":"Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma\u2014a strategy to increase resectability. Ann Surg Oncol. 2007;14(12):3301\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1698_CR20","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1245\/s10434-022-12530-z","volume":"30","author":"XD Zhu","year":"2023","unstructured":"Zhu XD, Huang C, Shen YH, Xu B, Ge NL, Ji Y, Qu XD, Chen L, Chen Y, Li ML, Zhu JJ, Tang ZY, Zhou J, Fan J, Sun HC. Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma. Ann Surg Oncol. 2023;30(5):2782\u201390.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1698_CR21","doi-asserted-by":"crossref","first-page":"zrac114","DOI":"10.1093\/bjsopen\/zrac114","volume":"6","author":"WF Qu","year":"2022","unstructured":"Qu WF, Ding ZB, Qu XD, Tang Z, Zhu GQ, Fu XT, Zhang ZH, Zhang X, Huang A, Tang M, Tian MX, Jiang XF, Huang R, Tao CY, Fang Y, Gao J, Wu XL, Zhou J, Fan J, Liu WR, Shi YH. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open. 2022;6(5):zrac114.","journal-title":"BJS Open."},{"key":"1698_CR22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/hbsn-21-328","volume":"11","author":"HC Sun","year":"2022","unstructured":"Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W, Zhao M, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11:227\u201352.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1698_CR23","doi-asserted-by":"crossref","unstructured":"Bi X, Zhao H, Zhao H, Li G, Wang X, Chen B, Zhang W, Che X, Huang Z, Han Y, Jiang L, Sun Y, Yang Z, Zhou J, Zhang Y, Zhu Z, Chen M, Cheng S, Cai J. Consensus of chinese experts on neoadjuvant and conversion therapies for hepatocellular carcinoma: 2023 update. liver cancer 2024.","DOI":"10.1159\/000541249"},{"key":"1698_CR24","volume":"95","author":"K Wang","year":"2016","unstructured":"Wang K, Guo WX, Chen MS, Mao YL, Sun BC, Shi J, Zhang YJ, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter. Propens Mathch Score Anal Med (Baltimore). 2016;95: e3015.","journal-title":"Propens Mathch Score Anal Med (Baltimore)"},{"key":"1698_CR25","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960\u201370.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1698_CR26","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/1078-0432.CCR-18-3477","volume":"25","author":"Z Cai","year":"2019","unstructured":"Cai Z, Chen G, Zeng Y, Dong X, Li Z, Huang Y, Xin F, Qiu L, Xu H, Zhang W, Su X, Liu X, Liu J. Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma. Clin Cancer Res. 2019;25(17):5284\u201394.","journal-title":"Clin Cancer Res"},{"key":"1698_CR27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12885-021-08103-0","volume":"21","author":"SK Oversoe","year":"2021","unstructured":"Oversoe SK, Clement MS, Weber B, Gronbaek H, Hamilton-Dutoit SJ, Sorensen BS, Kelsen J. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. BMC Cancer. 2021;21:376.","journal-title":"BMC Cancer"},{"key":"1698_CR28","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/cancers14143367","volume":"14","author":"T Matsumae","year":"2022","unstructured":"Matsumae T, Kodama T, Myojin Y, Maesaka K, Sakamori R, Takuwa A, Oku K, et al. Circulating cell-free DNA profiling predicts the therapeutic outcome in advanced hepatocellular carcinoma patients treated with combination immunotherapy. Cancers Basel. 2022;14:3367.","journal-title":"Cancers Basel"},{"key":"1698_CR29","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.3390\/cancers15215220","volume":"15","author":"R Raj","year":"2023","unstructured":"Raj R, Wehrle CJ, Aykun N, Stitzel H, Ma WW, Krishnamurthi S, Estfan B, et al. Immunotherapy plus locoregional therapy leading to curative-intent hepatectomy in HCC: proof of concept producing durable survival benefits detectable with liquid biopsy. Cancers (Basel). 2023;15:5220.","journal-title":"Cancers (Basel)"},{"key":"1698_CR30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/imt-2022-0168","volume":"15","author":"X Zhou","year":"2023","unstructured":"Zhou X, Cao J, Topatana W, Xie T, Chen T, Hu J, Li S, et al. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis. Immunotherapy. 2023;15:353\u201365.","journal-title":"Immunotherapy"},{"key":"1698_CR31","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.3390\/ijms22094710","volume":"22","author":"DJ Park","year":"2021","unstructured":"Park DJ, Sung PS, Lee GW, Cho S, Kim SM, Kang BY, Hur W, et al. Preferential expression of programmed death ligand 1 protein in tumor-associated macrophages and its potential role in immunotherapy for hepatocellular carcinoma. Int J Mol Sci. 2021;22:4710.","journal-title":"Int J Mol Sci"},{"key":"1698_CR32","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109244","volume":"112","author":"J Zheng","year":"2022","unstructured":"Zheng J, Shao M, Yang W, Ren J, Chen X, Yang H. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: a systematic review and meta-analysis. Int Immunopharmacol. 2022;112: 109244.","journal-title":"Int Immunopharmacol"},{"key":"1698_CR33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/liv.14706","volume":"41","author":"CN Wong","year":"2021","unstructured":"Wong CN, Fessas P, Dominy K, Mauri FA, Kaneko T, Parcq PD, Khorashad J, et al. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int. 2021;41:192\u2013203.","journal-title":"Liver Int"},{"key":"1698_CR34","doi-asserted-by":"crossref","first-page":"77415","DOI":"10.18632\/oncotarget.20492","volume":"8","author":"ST Kim","year":"2017","unstructured":"Kim ST, Klempner SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, et al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget. 2017;8:77415\u201323.","journal-title":"Oncotarget"},{"key":"1698_CR35","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362: k3529.","journal-title":"BMJ"},{"key":"1698_CR36","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.3390\/cancers12123830","volume":"12","author":"S Spahn","year":"2020","unstructured":"Spahn S, Roessler D, Pompilia R, Gabernet G, Gladstone BP, Horger M, Biskup S, et al. Clinical and genetic tumor characteristics of responding and non-responding patients to PD-1 Inhibition in hepatocellular carcinoma. Cancers (Basel). 2020;12:3830.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1698_CR37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/14728214.2024.2430493","volume":"29","author":"L Stella","year":"2024","unstructured":"Stella L, Hollande C, Merabet YB, Fakhouri H, Leclerc V, Ponziani FR, Bouattour M. Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results. Expert Opin Emerg Drugs. 2024;29(4):369\u201382.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"10474","key":"1698_CR38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, \u017botkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R. EMERALD-1 investigators. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405(10474):216\u201332.","journal-title":"Lancet"},{"key":"1698_CR39","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1097\/JS9.0000000000000654","volume":"109","author":"M Deng","year":"2023","unstructured":"Deng M, Cai H, He B, Guan R, Lee C, Guo R. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study. Int J Surg. 2023;109:3303\u201311.","journal-title":"Int J Surg"},{"key":"1698_CR40","volume":"2","author":"B Li","year":"2021","unstructured":"Li B, Qiu J, Zheng Y, Shi Y, Zou R, He W, Yuan Y, et al. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma. Ann Surg Open. 2021;2: e057.","journal-title":"Ann Surg Open"},{"key":"1698_CR41","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2147\/JHC.S432062","volume":"10","author":"B Yu","year":"2023","unstructured":"Yu B, Zhang N, Feng Y, Zhang Y, Zhang T, Wang L. Hepatectomy after conversion therapy with hepatic arterial infusion chemotherapy, tyrosine kinase inhibitors and anti-PD-1 antibodies for initially unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:1709\u201321.","journal-title":"J Hepatocell Carcinoma"},{"key":"1698_CR42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/JHC.S379326","volume":"9","author":"J Wang","year":"2022","unstructured":"Wang J, Zheng Z, Wu T, Li W, Wang J, Pan Y, Peng W, et al. Hepatic arterial infusion chemotherapy as a timing strategy for conversion surgery to treat hepatocellular carcinoma: a single-center real-world study. J Hepatocell Carcinoma. 2022;9:999\u20131010.","journal-title":"J Hepatocell Carcinoma"},{"key":"1698_CR43","doi-asserted-by":"crossref","first-page":"1004652","DOI":"10.3389\/fonc.2022.1004652","volume":"12","author":"L Luo","year":"2022","unstructured":"Luo L, Xiao Y, Zhu G, Huang A, Song S, Wang T, Ge X, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a tertiary medical center experience. Front Oncol. 2022;12:1004652.","journal-title":"Front Oncol"},{"key":"1698_CR44","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hpb.2021.12.013","volume":"24","author":"T Baker","year":"2022","unstructured":"Baker T, Tabrizian P, Zendejas I, Gamblin TC, Kazimi M, Boudjema K, Geller D, et al. Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. HPB (Oxford). 2022;24:1007\u201318.","journal-title":"HPB (Oxford)"},{"key":"1698_CR45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12328-023-01768-z","volume":"16","author":"S Takakusagi","year":"2023","unstructured":"Takakusagi S, Tanaka H, Naganuma A, Kakizaki S, Shibuya K, Ohno T, Takagi H, et al. Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment. Clin J Gastroenterol. 2023;16:407\u201315.","journal-title":"Clin J Gastroenterol"},{"key":"1698_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.12.025","volume":"133","author":"HK Byun","year":"2019","unstructured":"Byun HK, Kim HJ, Im YR, Kim DY, Han KH, Seong J. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. Radiother Oncol. 2019;133:1\u20138.","journal-title":"Radiother Oncol"},{"issue":"4","key":"1698_CR47","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16184","volume":"45","author":"L Tselikas","year":"2025","unstructured":"Tselikas L, Ronot M. Trans-arterial radioembolisation for HCC: personalised dosimetry beyond yttrium 90. Liver Int. 2025;45(4): e16184.","journal-title":"Liver Int"},{"key":"1698_CR48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000514313","volume":"10","author":"XD Zhu","year":"2021","unstructured":"Zhu XD, Huang C, Shen YH, Ji Y, Ge NL, Qu XD, Chen L, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer. 2021;10:320\u20139.","journal-title":"Liver Cancer"},{"key":"1698_CR49","doi-asserted-by":"crossref","first-page":"1073133","DOI":"10.3389\/fimmu.2023.1073133","volume":"14","author":"H Zeng","year":"2023","unstructured":"Zeng H, Xu Q, Wang J, Xu X, Luo J, Zhang L, Luo C, et al. The effect of anti-PD-1\/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. Front Immunol. 2023;14:1073133.","journal-title":"Front Immunol"},{"key":"1698_CR50","first-page":"175883592312062","volume":"15","author":"Q Liu","year":"2023","unstructured":"Liu Q, Li R, Li L, Wang G, Ji S, Zheng X, Jia X, et al. Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience. Ther Adv Med Oncol. 2023;15:17588359231206274.","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"1698_CR51","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","volume":"22","author":"PR Galle","year":"2021","unstructured":"Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991\u20131001.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1698_CR52","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J. ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390.","journal-title":"Lancet Oncol"},{"issue":"10408","key":"1698_CR53","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A. CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346.","journal-title":"Lancet"},{"issue":"12","key":"1698_CR54","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS. LEAP-002 investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1698_CR55","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","volume":"23","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995\u20131008.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1698_CR56","volume":"31","author":"X Chen","year":"2022","unstructured":"Chen X, Li W, Wu X, Zhao F, Wang D, Wu H, Gu Y, Li X, Qian X, Hu J, Li C, Xia Y, Rao J, Dai X, Shao Q, Tang J, Li X, Shu Y. Safety and efficacy of sintilimab and anlotinib as first line treatment for advanced hepatocellular carcinoma (KEEP-G04): a single-arm phase 2 study. Front Oncol. 2022;31(12): 909035.","journal-title":"Front Oncol"},{"issue":"suppl 15","key":"1698_CR57","doi-asserted-by":"crossref","first-page":"abstra4078","DOI":"10.1200\/JCO.2021.39.15_suppl.4078","volume":"39","author":"AB El-Khoueiry","year":"2021","unstructured":"El-Khoueiry AB, Kim RD, Harris WP, Sung MW, Waldschmidt D, Cabrera R. Updated results of a phase 1b study of regorafenib (REG) 80 mg\/day or 120 mg\/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(suppl 15):abstra4078.","journal-title":"J Clin Oncol"},{"key":"1698_CR58","doi-asserted-by":"crossref","unstructured":"Lin HF, Ma J, Zhuo MY, Zhang CS, Luo JR, Zhuang ZM, Yang LH. Anlotinib plus toripalimab as first-line treatment for patients with unresectable hepatocellular carcinoma: updated results of the ALTER-H003 trial.2023 ASCO-GI. 568P.","DOI":"10.1200\/JCO.2023.41.4_suppl.568"},{"issue":"14","key":"1698_CR59","doi-asserted-by":"crossref","first-page":"1238667","DOI":"10.3389\/fimmu.2023.1238667","volume":"24","author":"Q Qiao","year":"2023","unstructured":"Qiao Q, Han C, Ye S, Li J, Shao G, Bai Y, Xu A, Sun M, Wang W, Wu J, Huang M, Song L, Huang L, Liu T, Liu W, Wang ZM, Li B, Xia M, Bai L. The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib\/II single-arm clinical trial. Front Immunol. 2023;24(14):1238667.","journal-title":"Front Immunol"},{"issue":"16","key":"1698_CR60","first-page":"4107","volume":"40","author":"P Thuss-Patience","year":"2022","unstructured":"Thuss-Patience P, et al. IMMUNIB trial (AIO-HEP-0218\/ass): a single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced stage hepatocellular carcinoma (HCC). JCO. 2022;40(16):4107.","journal-title":"JCO"},{"issue":"16_suppl","key":"1698_CR61","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1200\/JCO.2022.40.16_suppl.4115","volume":"40","author":"X Baocai Xing","year":"2022","unstructured":"Baocai Xing X, Da YZ, Ma Y. A phase II study combining KN046 (an anti-PD-L1\/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): updated efficacy and safety results. JCO. 2022;40(16_suppl):4115.","journal-title":"JCO"},{"issue":"3","key":"1698_CR62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000514420","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J. Avelumab in combination with Axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: results from the phase 1b VEGF liver 100 trial. Liver Cancer. 2021;10(3):249\u201359.","journal-title":"Liver Cancer"},{"issue":"4","key":"1698_CR63","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, Liu J, Ren Z, Xiong J, Mao X, Zhang L, Yang J, Li L, Chen X, Wang Z, Gu K, Chen X, Pan Z, Ma K, Zhou X, Yu Z, Li E, Yin G, Zhang X, Wang S, Wang Q. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, Phase II Trial. Clin Cancer Res. 2021;27(4):1003\u201311.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1698_CR64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"TQ Zhang","year":"2023","unstructured":"Zhang TQ, Geng ZJ, Zuo MX, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona clinic liver cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023;8(1):413.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1698_CR65","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571\u201380.","journal-title":"Lancet Oncol"},{"key":"1698_CR66","volume":"12","author":"Y Pei","year":"2022","unstructured":"Pei Y, Li W, Wang Z, Liu J. Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: a systematic review and meta-analysis. Front Oncol. 2022;12: 978823.","journal-title":"Front Oncol"},{"key":"1698_CR67","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12885-023-10955-7","volume":"23","author":"B Zhang","year":"2023","unstructured":"Zhang B, Shi X, Cui K, Li Z, Li L, Liu Z, Zhang C, et al. Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients. BMC Cancer. 2023;23:465.","journal-title":"BMC Cancer"},{"key":"1698_CR68","volume":"67","author":"XK Wu","year":"2024","unstructured":"Wu XK, Yang LF, Chen YF, Chen ZW, Lu H, Shen XY, Chi MH, Wang L, Zhang H, Chen JF, Huang JY, Zeng YY, Yan ML, Zhang ZB. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study. EClinicalMedicine. 2024;67: 102367.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1698_CR69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4251\/wjgo.v15.i1.1","volume":"15","author":"J Liang","year":"2023","unstructured":"Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol. 2023;15(1):1\u201318.","journal-title":"World J Gastrointest Oncol"},{"issue":"7","key":"1698_CR70","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/bjs\/znac334","volume":"110","author":"W Peng","year":"2023","unstructured":"Peng W, Zhang X, Li C, Zhu X, Li Q, Chen W, Lu W, Liu C, Zhou Y, Shi Y, Wen T, Sun X. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma. Br J Surg. 2023;110(7):746\u20138.","journal-title":"Br J Surg"},{"issue":"13","key":"1698_CR71","doi-asserted-by":"crossref","first-page":"1115109","DOI":"10.3389\/fonc.2023.1115109","volume":"16","author":"L Wang","year":"2023","unstructured":"Wang L, Wang H, Cui Y, Liu M, Jin K, Xu D, Wang K, Xing B. Sintilimab plus Lenvatinib conversion therapy for intermediate\/locally advanced hepatocellular carcinoma: a phase 2 study. Front Oncol. 2023;16(13):1115109.","journal-title":"Front Oncol"},{"key":"1698_CR72","first-page":"715P","volume":"2022","author":"X-y Zhang","year":"2022","unstructured":"Zhang X-y, et al. The safety and efficacy of Lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: interim results from a multicenter prospective cohort study. ESMO. 2022;2022:715P.","journal-title":"ESMO"},{"key":"1698_CR73","unstructured":"Conversion hepatectomy for hepatocellular carcinoma with inadequate future- remnant-liver after portal vein ligation in combination with apatinib plus camrelizumab: a single-arm prospective pilot study (PLACES).2021 ASCO e1613257."},{"key":"1698_CR74","doi-asserted-by":"crossref","unstructured":"Zhang Z, et al. Transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma (uHCC): a prospective, single-arm, multicenter study. 2023 ASCO annual meeting, Poster 4072","DOI":"10.1200\/JCO.2023.41.16_suppl.4072"},{"issue":"14","key":"1698_CR75","doi-asserted-by":"crossref","first-page":"1188308","DOI":"10.3389\/fimmu.2023.1188308","volume":"21","author":"J Li","year":"2023","unstructured":"Li J, Kong M, Yu G, Wang S, Shi Z, Han H, Lin Y, Shi J, Song J. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma. Front Immunol. 2023;21(14):1188308.","journal-title":"Front Immunol"},{"key":"1698_CR76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4073","author":"D Liu","year":"2022","unstructured":"Liu D, et al. Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): a prospective, single-arm phase II trial. JCO. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4073.","journal-title":"JCO"},{"issue":"2","key":"1698_CR77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):169\u201378.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"1698_CR78","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/JHC.S404675","volume":"22","author":"L Gan","year":"2023","unstructured":"Gan L, Lang M, Tian X, Ren S, Li G, Liu Y, Han R, Zhu K, Li H, Wu Q, Cui Y, Zhang W, Fang F, Li Q, Song T. A retrospective analysis of conversion therapy with lenvatinib, sintilimab, and arterially-directed therapy in patients with initially unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;22(10):673\u201386.","journal-title":"J Hepatocell Carcinoma"},{"issue":"10","key":"1698_CR79","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2147\/JHC.S432062","volume":"4","author":"B Yu","year":"2023","unstructured":"Yu B, Zhang N, Feng Y, Zhang Y, Zhang T, Wang L. Hepatectomy after conversion therapy with hepatic arterial infusion chemotherapy, tyrosine kinase inhibitors and anti-PD-1 antibodies for initially unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;4(10):1709\u201321.","journal-title":"J Hepatocell Carcinoma"},{"key":"1698_CR80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4083","author":"M He","year":"2021","unstructured":"He M, Ming S, Lai Z, Li Q. A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study). JCO. 2021. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4083.","journal-title":"JCO"},{"key":"1698_CR81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e16203","author":"Y Cao","year":"2023","unstructured":"Cao Y, Zhang X, Yue Y, Peng J, Li B, Shi J, Tang M, Chen C, Su K, Zhang L, Cheng C, Yu D. Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): a prospective, single-arm, phase II study. JCO. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16203.","journal-title":"JCO"},{"key":"1698_CR82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.558","author":"T Liang","year":"2023","unstructured":"Liang T, Chen Y, Huang X, Wendi H, Li X, Sun J, Shen Y, Zhang M, Jian W, Gao S, Jun Y, Que R, Zhang Y, Yang F, Xia W, Zhang A, Tang X, Bai X. Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: an open-label, single-arm, phase 2 study\u2014The CISLD-12 study. JCO. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.558.","journal-title":"JCO"},{"key":"1698_CR83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e16165","author":"W Zhang","year":"2023","unstructured":"Zhang W, Gao W, Liu C, Li G, Zhang Q. Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): a prospective, single-arm phase II trial (DoHAICs study). JCO. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16165.","journal-title":"JCO"},{"key":"1698_CR84","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960\u201370.","journal-title":"J Clin Oncol"},{"key":"1698_CR85","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1200\/JOP.2015.009407","volume":"12","author":"M Dhir","year":"2016","unstructured":"Dhir M, Sasson AR. Surgical management of liver metastases from colorectal cancer. J Oncol Pract. 2016;12:33\u20139.","journal-title":"J Oncol Pract"},{"key":"1698_CR86","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2147\/JHC.S442341","volume":"10","author":"JY Wu","year":"2023","unstructured":"Wu JY, Wu JY, Liu DY, Li H, Zhuang SW, Li B, Zhou JY, et al. Clinical complete response after conversion therapy for unresectable hepatocellular carcinoma: is salvage hepatectomy necessary? J Hepatocell Carcinoma. 2023;10:2161\u201371.","journal-title":"J Hepatocell Carcinoma"},{"issue":"5","key":"1698_CR87","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1097\/JS9.0000000000001155","volume":"110","author":"B Li","year":"2024","unstructured":"Li B, Wang C, He W, Qiu J, Zheng Y, Zou R, Lin Z, et al. Watch-and-Wait strategy vs resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study. Int J Surg. 2024;110(5):2545\u201355.","journal-title":"Int J Surg"},{"key":"1698_CR88","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1245\/s10434-024-14944-3","volume":"31","author":"JY Wu","year":"2024","unstructured":"Wu JY, Wu JY, Fu YK, Ou XY, Li SQ, Zhang ZB, Zhou JY, et al. Outcomes of salvage surgery versus non-salvage surgery for initially unresectable hepatocellular carcinoma after conversion therapy with transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibody: a multicenter retrospective study. Ann Surg Oncol. 2024;31:3073\u201383.","journal-title":"Ann Surg Oncol"},{"key":"1698_CR89","doi-asserted-by":"crossref","first-page":"620","DOI":"10.21037\/hbsn-22-233","volume":"11","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao H, Sun H. It\u2019s time to propose a uniform criteria for determining \u201cclinical complete response\u201d in hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2022;11:620\u20132.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1698_CR90","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344\u201354.","journal-title":"Lancet Oncol"},{"key":"1698_CR91","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835\u201347.","journal-title":"Lancet"},{"key":"1698_CR92","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.annonc.2024.08.2279","volume":"35","author":"A Yopp","year":"2024","unstructured":"Yopp A, et al. LBA39: updated efficacy and safety data from IMbrave050: phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Ann Oncol. 2024;35:1230.","journal-title":"Ann Oncol"},{"issue":"3","key":"1698_CR93","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"key":"1698_CR94","unstructured":"National Health Commission of the People's Republic of China. Clinical practice guideline for primary liver cancer (2024 Edition). Chin J Hepatol 2024; 32(7): 581\u2013630."},{"key":"1698_CR95","doi-asserted-by":"publisher","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.","DOI":"10.1016\/S0140-6736(16)32453-9"},{"issue":"1","key":"1698_CR96","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Kl\u00fcmpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54\u201363.","journal-title":"N Engl J Med"},{"issue":"2","key":"1698_CR97","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282\u201396.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1698_CR98","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL. KEYNOTE-240 investigators. Pembrolizumab As second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193\u2013202.","journal-title":"J Clin Oncol"},{"key":"1698_CR99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.02.009","volume":"167","author":"M Kudo","year":"2022","unstructured":"Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Yau T, Gurary EB, Siegel AB, Wang A, Cheng AL, Zhu AX. KEYNOTE-224 investigators. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer. 2022;167:1\u201312.","journal-title":"Eur J Cancer"},{"issue":"10088","key":"1698_CR100","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Rd WTH, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"issue":"11","key":"1698_CR101","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11): e204564.","journal-title":"JAMA Oncol"},{"key":"1698_CR102","first-page":"oyae342","volume":"14","author":"P Marell","year":"2024","unstructured":"Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH. Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. Oncologist. 2024;14:oyae342.","journal-title":"Oncologist"},{"issue":"34","key":"1698_CR103","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/JCO.24.00645","volume":"42","author":"YC Shen","year":"2024","unstructured":"Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab. J Clin Oncol. 2024;42(34):4060\u201370.","journal-title":"J Clin Oncol"},{"key":"1698_CR104","doi-asserted-by":"crossref","unstructured":"Wang K et al. 169P: conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab. ESMO Asia 2023.","DOI":"10.1016\/j.annonc.2023.10.304"},{"issue":"1","key":"1698_CR105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00423-023-02993-3","volume":"408","author":"ZC Qiu","year":"2023","unstructured":"Qiu ZC, Li C, Zhang Y, Xie F, Yu Y, Leng SS, Chen TH, Wen TF. Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection. Langenbecks Arch Surg. 2023;408(1):250.","journal-title":"Langenbecks Arch Surg"},{"key":"1698_CR106","doi-asserted-by":"crossref","unstructured":"Yang XR, et al. Hepatocellular carcinoma (HCC) Utilizing personalized tumor-specific methylation haplotypes of circulating tumor DNA for monitoring minimal residual disease in hepatocellular carcinoma patients after curative resection. ESMO 2024 Abstract 958P.","DOI":"10.1016\/j.annonc.2024.08.1018"},{"issue":"10","key":"1698_CR107","volume":"14","author":"J Yang","year":"2020","unstructured":"Yang J, Bao Y, Chen W, Duan Y, Sun D. Nomogram based on systemic immune inflammation index and prognostic nutrition index predicts recurrence of hepatocellular carcinoma after surgery. Front Oncol. 2020;14(10): 551668.","journal-title":"Front Oncol"},{"issue":"15","key":"1698_CR108","doi-asserted-by":"crossref","first-page":"1308543","DOI":"10.3389\/fimmu.2024.1308543","volume":"16","author":"KY Lin","year":"2024","unstructured":"Lin KY, Zhang JX, Lin ZW, Chen QJ, Luo LP, Chen JH, Wang K, Tai S, Zhang ZB, Wang SF, Li JD, Wang K, Zheng L, Zheng SM, Wu MM, Lin KC, Yang T, Zeng YY. Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study. Front Immunol. 2024;16(15):1308543.","journal-title":"Front Immunol"},{"issue":"5","key":"1698_CR109","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1007\/s12072-024-10680-8","volume":"18","author":"M Chuma","year":"2024","unstructured":"Chuma M, Uojima H, Toyoda H, Hiraoka A, Arase Y, Atsukawa M, Itokawa N, Okubo T, Tada T, Numata K, Morimoto M, Sugimori M, Nozaki A, Iwasaki S, Yasuda S, Koshiyama Y, Mishima Y, Tsuruya K, Tokoro C, Miura Y, Hidaka H, Kumada T, Kusano C, Kagawa T, Maeda S. Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma. Hepatol Int. 2024;18(5):1472\u201385.","journal-title":"Hepatol Int"},{"issue":"7","key":"1698_CR110","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/cancers16071328","volume":"16","author":"Y Shirane","year":"2024","unstructured":"Shirane Y, Fujii Y, Ono A, Nakahara H, Hayes CN, Miura R, Murakami S, Sakamoto N, Uchikawa S, Fujino H, Nakahara T, Murakami E, Yamauchi M, Miki D, Kawaoka T, Arihiro K, Tsuge M, Oka S. Peripheral T cell subpopulations as a potential surrogate biomarker during atezolizumab plus bevacizumab treatment for hepatocellular carcinoma. Cancers (Basel). 2024;16(7):1328.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1698_CR111","first-page":"298","volume":"12","author":"QF Chen","year":"2024","unstructured":"Chen QF, Chen S, Chen M, Lyu N, Zhao M. Improving the conversion success rate of hepatocellular carcinoma: focus on the use of combination therapy with a high objective response rate. J Clin Transl Hepatol. 2024;12(3):298\u2013304.","journal-title":"J Clin Transl Hepatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01698-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01698-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01698-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:49:18Z","timestamp":1764917358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01698-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1698"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01698-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]},"assertion":[{"value":"18 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"169"}}